



Precision BioSciences' Response to Collectis Lawsuit

RESEARCH TRIANGLE PARK, North Carolina, Mar. 19, 2008 – Precision BioSciences, Inc. today reacted to a patent infringement lawsuit filed by Collectis SA, of Romainville, France. Precision's management described Collectis' allegations as unfounded and stated that no such infringement has occurred. "Precision has reviewed Collectis' patent claims. It is clear that our next-generation genome engineering technology is demonstrably distinct from the dated technology covered by Collectis' patents," said Matthew Kane, CEO of Precision BioSciences. "This lawsuit appears to stem from a fundamental misunderstanding of Precision's DNE technology and how it is employed. Our DNE technology is the new gold standard in genome engineering and does not make use of the methods claimed by Collectis." In response to the lawsuit, Precision has engaged WilmerHale, a law firm with one of the nation's premier intellectual property litigation groups. Mr. Kane concluded, "We deny any wrongdoing and will vigorously defend ourselves against any efforts to stifle the lawful practice of our cutting-edge DNE technology."

About Precision BioSciences

Precision's mission is to utilize its engineered endonuclease technology to become the world leader in the field of genomic molecular biology. Precision's proprietary *Directed Nuclease Editor*[™] (DNE) technology enables the production of genome editing enzymes that can be customized to modify essentially any gene in plant or animal cells.

Precision's unique approach is rapid and robust. With production time as short as two weeks, Precision BioSciences has already produced hundreds of custom endonucleases for partners and internal development that were designed to target naturally occurring sequences within genomes. Precision is focused on utilizing DNE technology to insert, remove, modify and regulate DNA for therapeutic, agricultural, and diagnostic applications. For additional information, please visit www.precisionbiosciences.com.

For more information:

Matthew Kane
Chief Executive Officer
Precision BioSciences, Inc.
919-314-5512